Ipsen loses another legal fight over biologic classification; Viking announces plan to bring injectable GLP-1 into Phase 3 study sooner; GE HealthCare makes moves with Amazon Web Services to develop Generative AI services.
Five things for pharma marketers to know for Thursday morning
What does Google’s third-party cookie decision mean for medical marketers? CVS Caremark agrees to $45 million settlement with Illinois; Gilead’s twice-yearly shots used to treat HIV show 100% efficacy in women.
Five things for pharma marketers to know for Wednesday morning
Healthcare leaders react to Biden’s withdrawal from the 2024 election; Agilent to buy Biovectra for $925 million; WuXi AppTec increases congressional lobbying effort.
Five things for pharma marketers to know for Thursday morning
Eli Lilly’s Mounjaro has limited availability through February; Samsung Biologics says its net profit fell 21.4% in Q4 2023 due largely to a one-off factor; The FDA denies approval for a newer formulation of tesamorelin that Theratechnologies proposed.
Five things for pharma marketers to know for Monday morning
Will Bernie Sanders subpoena Big Pharma execs?; Drugmakers raise the list prices for Ozempic and Mounjaro; Scientists identify a persistent change in a handful of blood proteins in people with long COVID.
Five things for pharma marketers to know on Tuesday morning
Novartis in talks to buy Cytokinetics; Boston Scientific acquires medtech company Axonics in $3.7 billion deal; Lilly’s Zepbound obesity drug reaches 25,000 new prescriptions mark.
Five things for pharma marketers to know on Tuesday